Reaction
Vocal Cord Paralysis reporting signals
As of the last recalculation, Vocal Cord Paralysis appears in 1,775 FAERS reports alongside 39 co-occurring drug terms. The strongest observed disproportionality signal is ATOVAQUONE (PRR 20.5).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Atovaquone | 14 | 20.5 | 20.6 |
| Axicabtagene Ciloleucel | 15 | 18.0 | 18.0 |
| Botulinum Toxin Type A | 17 | 16.2 | 16.2 |
| Pegaspargase | 14 | 13.5 | 13.5 |
| Mesna Injection | 9 | 12.8 | 12.8 |
| Mesna | 9 | 12.6 | 12.6 |
| Bleomycin Sulfate | 11 | 12.6 | 12.6 |
| Mercaptopurine | 18 | 12.3 | 12.3 |
| Vincristine Sulfate | 28 | 11.4 | 11.4 |
| Ado-Trastuzumab Emtansine | 8 | 11.2 | 11.2 |
| Rocuronium Bromide | 11 | 11.0 | 11.0 |
| Fulvestrant | 28 | 10.1 | 10.1 |
| Sevoflurane | 7 | 9.9 | 9.9 |
| Micafungin Sodium | 7 | 9.7 | 9.7 |
| Gefitinib | 6 | 7.8 | 7.8 |
| Oxazepam | 14 | 7.7 | 7.7 |
| Bupivacaine | 6 | 7.6 | 7.6 |
| Oxaliplatin | 46 | 7.4 | 7.4 |
| Alteplase | 9 | 7.1 | 7.1 |
| Trastuzumab | 40 | 7.0 | 7.0 |
| Ribociclib | 18 | 6.7 | 6.7 |
| Osimertinib | 17 | 6.3 | 6.3 |
| Olaparib | 11 | 6.2 | 6.2 |
| Lenvatinib | 16 | 5.8 | 5.8 |
| Paclitaxel | 47 | 5.7 | 5.7 |
| Capecitabine | 42 | 5.5 | 5.5 |
| Paclitaxel (Aibumin-Bound) | 37 | 5.4 | 5.4 |
| Fluorouracil Cream, 0.5% | 33 | 5.2 | 5.2 |
| Dabrafenib | 9 | 5.0 | 5.0 |
| Erlotinib | 4 | 4.9 | 4.9 |
| Erlotinib Hydrochloride | 5 | 4.7 | 4.7 |
| Crizotinib | 5 | 4.6 | 4.6 |
| Onabotulinumtoxina | 29 | 4.5 | 4.5 |
| Fluticasone Furoate, Umeclidinium Bromide And Vilanterol Trifenatate | 14 | 4.0 | 4.0 |
| Nivolumab | 31 | 3.8 | 3.8 |
| Fam-Trastuzumab Deruxtecan-Nxki | 3 | 3.5 | 3.5 |
| Palbociclib | 28 | 3.5 | 3.5 |
| Cabozantinib | 13 | 3.2 | 3.2 |
| Palivizumab | 4 | 3.1 | 3.1 |